Pharmacokinetics of tolamolol in the treatment of hypertension

Abstract

Tolamolol was administered in a "double-blind" study to fifteen hypertensive patients by dose-titration against arterial blood pressure. Mean steady-state plasma tolamolol concentrations (Css) were determined for each patient from the area under the plasma concentration--time curve during a dosage interval whilst patients were receiving optimal tolamolol doses. No significant correlation was observed between daily tolamolol dose and Css; the relationship between fall in lying mean arterial pressure and Css also failed to reach conventional levels of statistical significance, but Css was observed to be correlated with the fall in standing pressure. The results suggest that plasma concentrations in excess of 200 ng/ml may be required to achieve an effective hypothensive response with the drug.

Exploring Sex Differences of Beta-Blockers in the Treatment of Hypertension: A Systematic Review and Meta-Analysis

“…[58]; Nebivolol 5 mg/day orally [95]; Indenolol 120 mg/day orally [96]; Propranolol 320 mg/day orally [97] and 72 mg/day i.v. [98]; Nadolol 320 mg/day orally [99]; Nipradilol 18 mg/day orally [100]; Bucindolol 200 mg/day orally [101]; Carteolol 60 mg/day orally [102]; Dilevalol 1600 mg/day orally [103]; Tolamolol 900 mg/day orally [104]; Celiprolol 400 mg/day orally [105]; Timolol 60 mg/day orally [106]. ** Control group: other antihypertensive treatment, placebo, or non-drug intervention.…”